Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-HCC: Neoadjuvant Ipilimumab and Nivolumab in Hepatocellular Carcinoma
NCT03682276Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Mar 2019
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in hepatocellular carcinoma (HCC), sponsored by Imperial College London. Primary endpoints: Delay to Surgery at Day 89 and Frequency of Treatment-related Adverse Events at Day 127. Started Mar 2019; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03682276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682276.